RVTY · 8-K · 20260804PR000022

Operating Income and Margins

REVVITY, INC. · 2026-08-04 · Importance 38 · Surprise 40 · In source text

Reported second-quarter GAAP operating income declined to $89 million from $91 million, and GAAP operating margin decreased to 12.2% from 12.6%. Pro forma operating income increased to $94 million from $85 million, raising pro forma operating margin to 13.2% from 12.4%. Pro forma adjusted operating income increased to $209 million from $180 million, and pro forma adjusted operating margin expanded to 29.3% from 26.5%, including $16 million of tariff-related refunds. Diagnostics adjusted operating income rose to $113 million from $89 million and its margin increased to 30.4% from 25.2%, while Life Sciences adjusted operating income fell to $112 million from $115 million and its margin declined to 31.1% from 31.6%.

Key facts

• GAAP operating income from continuing operations for the quarter: $89 million (includes $16 million of tariff related refunds). source
• Pro forma adjusted operating income for the quarter: $209 million (includes $16 million of tariff related refunds). source
• Adjusted operating income for the quarter: $211 million. source
• Pro forma operating income for the quarter: $94 million. source
• Life Sciences second quarter 2026 adjusted operating income: $112 million; adjusted operating profit margin: 31.1% of revenue. source
• Diagnostics second quarter 2026 adjusted operating income: $113 million; adjusted operating profit margin: 30.4% of revenue. source
• Three months ended July 5, 2026 adjusted operating income (As Reported): $211,009 (thousands); adjusted operating margin 28.9%. source
• Three months ended July 5, 2026 Life Sciences segment operating income: $111,534; margin 31.1%. source

Impact estimates